Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI Read more...
Rapid Micro Biosystems, Inc. an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today confirmed that it has received an unsolicited, non-binding proposal from Kennedy Lewis Investment Management LLC to acquire all of the outstanding shares of the Company for $5.00 per share in cash. Consistent with its fiduciary duties and in consultation with it Read more...
Exela Technologies, Inc. a business process automation (“BPA”) leader, announced today that one of its subsidiaries entered into an exclusive non-binding letter of intent (“LOI”) to form a stand-alone publicly listed company of its EMEA business, which has approximately $200 million in annual revenue. The news follows the June 6 announcement in which Exela declared its intention to sell in excess of $200 million of assets. The equity consideration of Exe Read more...
